AbbVie and ImmunoGen said Thursday that they have signed an agreement for AbbVie to acquire ImmunoGen and its ovarian cancer therapy Elahere.
Under the terms of the agreement, AbbVie will buy.
AbbVie s $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained (NYSE:ABBV) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
AbbVie has agreed to acquire cancer drugmaker ImmunoGen for $31.26 per share in cash, in a deal valuing the latter at roughly $10.1 billion, the companies said Thursday.
The deal includes.
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The European Medicines Agency has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.